NASDAQ:VCEL - Vericel Stock Price, Price Target & More

$11.80 -0.20 (-1.67 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$11.80

Today's Range$11.60 - $12.1750

52-Week Range$2.35 - $13.20

Volume610,920 shs

Average Volume940,579 shs

Market Capitalization$437.27 million

P/E Ratio-23.60

Dividend YieldN/A

Beta3.18

About Vericel (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:VCEL

CUSIPN/A

Webwww.vcel.com

Phone800-556-0311

Debt

Debt-to-Equity Ratio0.75%

Current Ratio3.86%

Quick Ratio3.57%

Price-To-Earnings

Trailing P/E Ratio-23.60

Forward P/E Ratio-34.71

P/E GrowthN/A

Sales & Book Value

Annual Sales$63.92 million

Price / Sales6.73

Cash FlowN/A

Price / CashN/A

Book Value$0.65 per share

Price / Book18.15

Profitability

EPS (Most Recent Fiscal Year)($0.50)

Net Income$-17,280,000.00

Net Margins-27.04%

Return on Equity-98.77%

Return on Assets-39.49%

Miscellaneous

Employees205

Outstanding Shares36,440,000

How to Become a New Pot Stock Millionaire

Vericel (NASDAQ:VCEL) Frequently Asked Questions

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

How were Vericel's earnings last quarter?

Vericel (NASDAQ:VCEL) issued its earnings results on Monday, March, 5th. The biotechnology company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.13. The biotechnology company had revenue of $23.35 million for the quarter. Vericel had a negative return on equity of 98.77% and a negative net margin of 27.04%. View Vericel's Earnings History.

When is Vericel's next earnings date?

Vericel is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Vericel.

What price target have analysts set for VCEL?

5 brokers have issued 12 month price objectives for Vericel's shares. Their predictions range from $13.00 to $15.00. On average, they anticipate Vericel's stock price to reach $14.25 in the next year. View Analyst Ratings for Vericel.

Who are some of Vericel's key competitors?

Some companies that are related to Vericel include La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Heska (HSKA), Fate Therapeutics (FATE), EntreMed (CASI), Voyager Therapeutics (VYGR), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Nightstar Therapeutics (NITE), Agenus (AGEN), Solid Biosciences (SLDB), Idera Pharmaceuticals (IDRA), Cellular Biomedicine (CBMG), Adverum Biotechnologies (ADVM) and NantKwest (NK).

Who are Vericel's key executives?

Vericel's management team includes the folowing people:

Mr. Dominick C. Colangelo Esq., Chief Exec. Officer, Pres, Treasurer and Director (Age 54)
Mr. Gerard J. Michel MS, MBA, Chief Financial Officer and VP of Corp. Devel. (Age 55)
Mr. Daniel R. Orlando, Chief Operating Officer (Age 53)
Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel and Corp. Sec.
Ms. Heidi Hassen, Sr. Director of HR

Has Vericel been receiving favorable news coverage?

Press coverage about VCEL stock has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vericel earned a news impact score of 0.11 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.09 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $11.80.

How big of a company is Vericel?

Vericel has a market capitalization of $437.27 million and generates $63.92 million in revenue each year. The biotechnology company earns $-17,280,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vericel employs 205 workers across the globe.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]

MarketBeat Community Rating for Vericel (VCEL)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		177 (Vote Outperform)
Underperform Votes:		169 (Vote Underperform)
Total Votes:		346

MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Vericel (NASDAQ:VCEL) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Vericel in the last 12 months. Their average twelve-month price target is $14.25, suggesting that the stock has a possible upside of 20.76%. The high price target for VCEL is $15.00 and the low price target for VCEL is $13.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.80	2.75	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$14.25	$14.00	$7.6667	$6.3333
Price Target Upside:	20.76% upside	18.14% upside	29.94% upside	5.56% upside

Vericel (NASDAQ:VCEL) Consensus Price Target History

Price Target History for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ:VCEL) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/4/2018	Leerink Swann	Initiated Coverage	Outperform -> Outperform	$15.00	High
3/6/2018	Needham & Company LLC	Boost Price Target	Buy -> Buy	$5.00 -> $15.00	High
3/6/2018	Ladenburg Thalmann	Downgrade	Buy -> Neutral		High
3/5/2018	BTIG Research	Reiterated Rating	Buy -> Buy	$8.00 -> $13.00	High
3/5/2018	Piper Jaffray	Boost Price Target	Overweight	$14.00	High

(Data available from 4/21/2016 forward)

Vericel (NASDAQ:VCEL) Earnings History and Estimates Chart

Earnings by Quarter for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ:VCEL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.31)
2019 EPS Consensus Estimate: ($0.05)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.16)	($0.16)	($0.16)
Q2 2018	1	($0.06)	($0.06)	($0.06)
Q3 2018	1	($0.11)	($0.11)	($0.11)
Q4 2018	1	$0.02	$0.02	$0.02
Q1 2019	1	($0.11)	($0.11)	($0.11)
Q2 2019	1	$0.01	$0.01	$0.01
Q3 2019	1	($0.05)	($0.05)	($0.05)
Q4 2019	1	$0.10	$0.10	$0.10

Vericel (NASDAQ VCEL) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018
3/5/2018	Q4 2017	($0.10)	$0.03		$23.35 million	View	Listen
11/7/2017	Q3 2017	($0.17)	($0.16)		$14.26 million	View	N/A
8/9/2017	Q2 2017	($0.24)	($0.08)		$16.95 million	View	Listen
5/10/2017	Q1 2017	($0.19)	($0.31)		$9.36 million	View	N/A
3/10/2017	Q4 2016	($0.22)	($0.14)		$16.52 million	View	N/A
11/7/2016	Q3	($0.28)	($0.38)		$10.93 million	View	Listen
8/8/2016	Q2 2016		($0.21)		$12.82 million	View	N/A
5/10/2016	Q116	($0.25)	($0.08)	$11.60 million	$14.10 million	View	Listen
3/14/2016	Q415	($0.15)	($0.28)	$17.36 million	$15.40 million	View	Listen
11/13/2015	Q315	($0.21)	($0.26)	$10.50 million	$11.30 million	View	Listen
8/12/2015	Q215	($0.13)	($0.16)	$11.31 million	$13.60 million	View	Listen
5/14/2015	Q115	($0.14)	($0.27)	$11.10 million	$10.80 million	View	Listen
3/23/2015	Q414	($0.47)	($0.17)	$10.70 million	$14.70 million	View	Listen
11/13/2014	Q314	($0.66)	($0.52)	$6.73 million	$9.66 million	View	N/A
8/14/2014	Q214	($1.59)	($0.94)	$2.50 million	$4.43 million	View	N/A
5/15/2014	Q114	($0.92)	($1.26)			View	N/A
3/13/2014	Q413	($1.34)	($0.97)	$0.0190 million	$0.0080 million	View	N/A
11/12/2013	Q3	($2.02)	($0.06)			View	Listen
8/7/2013	Q2 2013	($2.40)	($2.20)			View	N/A
5/8/2013	Q1 2013	($0.19)	($0.15)		$0.01 million	View	N/A
3/18/2013	Q4 2012	($4.60)	($4.00)			View	N/A
11/8/2012	Q3 2012	($4.80)	($4.40)			View	N/A
8/7/2012	Q2 2012	($4.60)	($5.40)			View	N/A
5/10/2012	Q1 2012	($4.00)	($4.56)			View	N/A
3/12/2012	Q4 2011	($3.80)	($4.06)			View	N/A
11/8/2011	Q3 2011	($3.60)	($1.00)			View	N/A
8/15/2011	Q2 2011	($3.40)	($3.88)			View	N/A
5/16/2011	Q1 2011	($3.80)	($2.58)			View	N/A
2/28/2011	Q4 2010	($3.40)	($8.86)			View	N/A
11/8/2010	Q3 2010	($3.60)	($4.12)			View	N/A
8/17/2010	Q2 2010	($2.80)	($3.62)			View	N/A
5/10/2010	Q1 2010		($3.18)			View	N/A
2/10/2010	Q4 2009		($4.16)			View	N/A
11/6/2009	Q3 2009		($3.68)			View	N/A
9/14/2009	Q2 2009		($4.80)			View	N/A
5/8/2009	Q1 2009		($4.32)			View	N/A
2/6/2009	Q4 2008		($4.80)			View	N/A
11/7/2008	Q3 2008		($4.64)			View	N/A
8/29/2008	Q2 2008	($6.40)	($5.92)			View	N/A
5/12/2008	Q1 2008	($6.40)	($6.08)			View	N/A
2/8/2008	Q4 2007	($6.40)	($6.40)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Vericel (NASDAQ:VCEL) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Vericel (NASDAQ VCEL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 36.91%

Insider Trading History for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ VCEL) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2018	Alan L Rubino	Director	Buy	890	$11.57	$10,297.30	165
3/28/2016	Consonance Capital Management	Major Shareholder	Sell	120,000	$5.39	$646,800.00
9/16/2014	Daniel Orlando	COO	Buy	9,804	$2.55	$25,000.20
9/16/2014	Dominick Colangelo	CEO	Buy	20,000	$2.55	$51,000.00

(Data available from 1/1/2013 forward)

Vericel (NASDAQ VCEL) News Headlines

Source:

Date	Headline
	$16.51 Million in Sales Expected for Vericel (VCEL) This Quarter www.americanbankingnews.com - April 19 at 2:28 AM
	Zacks: Brokerages Expect Vericel (VCEL) to Announce -$0.15 Earnings Per Share www.americanbankingnews.com - April 17 at 7:08 PM
	Q1 2018 EPS Estimates for Vericel (VCEL) Cut by Leerink Swann www.americanbankingnews.com - April 16 at 1:14 AM
	Vericel to Post Q2 2019 Earnings of $0.01 Per Share, Leerink Swann Forecasts (VCEL) www.americanbankingnews.com - April 13 at 9:41 AM
	Vericel (VCEL) Upgraded to Strong-Buy at BidaskClub www.americanbankingnews.com - April 13 at 9:39 AM
	Vericel Stock Looks to Break Out From Prior Highs finance.yahoo.com - April 13 at 9:33 AM
	Harry Boxer’s five biotech stocks to watch finance.yahoo.com - April 11 at 4:39 PM
	Will Vericel (VCEL) Continue to Surge Higher? April 11, 2018 www.zacks.com - April 11 at 9:51 AM
	Will Vericel (VCEL) Continue to Surge Higher? finance.yahoo.com - April 11 at 9:51 AM
	Vericel (VCEL) PT Set at $6.00 by BTIG Research www.americanbankingnews.com - April 11 at 12:43 AM
	Piper Jaffray Reaffirms "Buy" Rating for Vericel (VCEL) www.americanbankingnews.com - April 10 at 10:31 PM
	Vericel to Present at the 6th Annual Cell & Gene Therapy Investor Day finance.yahoo.com - April 10 at 9:38 AM
	Leerink Swann Weighs in on Vericel's Q1 2018 Earnings (VCEL) www.americanbankingnews.com - April 6 at 8:30 AM
	Vericel: Breakthrough Cell Therapy Fueling Rapid Growth seekingalpha.com - April 5 at 4:36 PM
	Today’s Research Reports on Trending Tickers: Vericel Corporation and RXi Pharmaceuticals finance.yahoo.com - April 5 at 9:18 AM
	Vericel (VCEL) Now Covered by Leerink Swann www.americanbankingnews.com - April 4 at 9:30 AM
	Vericel (VCEL) Upgraded by ValuEngine to Buy www.americanbankingnews.com - April 2 at 10:52 PM
	3 Biotech Stocks Hitting New Highs finance.yahoo.com - April 2 at 9:43 AM
	Vericel (VCEL) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - April 1 at 5:48 AM
	Analysts Anticipate Vericel (VCEL) to Post -$0.13 EPS www.americanbankingnews.com - March 31 at 7:14 PM
	Vericel (VCEL) Rating Reiterated by Piper Jaffray www.americanbankingnews.com - March 31 at 10:56 AM
	Vericel (VCEL) Given a $8.00 Price Target at BTIG Research www.americanbankingnews.com - March 31 at 12:46 AM
	Vericel (VCEL) Cut to Buy at BidaskClub www.americanbankingnews.com - March 30 at 11:07 AM
	Vericel (VCEL) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow seekingalpha.com - March 29 at 4:38 PM
	Vericel (VCEL) Presents At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference - Slideshow seekingalpha.com - March 29 at 9:36 AM
	Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical ... globenewswire.com - March 24 at 4:34 PM
	Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years finance.yahoo.com - March 23 at 9:14 AM
	Alan L. Rubino Purchases 890 Shares of Vericel Corp (VCEL) Stock www.americanbankingnews.com - March 20 at 1:24 PM
	Vericel to Present at the 17th Annual Needham Healthcare Conference - GlobeNewswire (press release) globenewswire.com - March 13 at 6:30 PM
	Vericel to Present at the 17th Annual Needham Healthcare Conference finance.yahoo.com - March 13 at 6:30 PM
	Vericel to Host Analyst and Investor Day on April 11, 2018 finance.yahoo.com - March 12 at 5:42 PM
	Vericel (VCEL) Lifted to "Strong-Buy" at BidaskClub www.americanbankingnews.com - March 11 at 2:23 PM
	Vericel to Present at BioCentury's 25th Annual Future Leaders in the Biotech Industry Conference - GlobeNewswire (press release) globenewswire.com - March 9 at 9:43 AM
	Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference finance.yahoo.com - March 9 at 9:43 AM
	Ladenburg Thalmann Downgrades Vericel Corporation (VCEL) to Neutral; Valuation Full www.streetinsider.com - March 8 at 9:34 AM
	Stock Traders Purchase Large Volume of Vericel Call Options (VCEL) www.americanbankingnews.com - March 7 at 7:26 AM
	Vericel Corp (VCEL) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 7 at 5:58 AM
	Vericel (VCEL) Downgraded by Ladenburg Thalmann Financial Services to Neutral www.americanbankingnews.com - March 7 at 12:00 AM
	Today’s Research Reports on Trending Tickers: GlycoMimetics, Inc. and Vericel Corporation finance.yahoo.com - March 6 at 9:07 AM
	Vericel (VCEL) Price Target Raised to $15.00 www.americanbankingnews.com - March 6 at 8:42 AM
	Vericel (VCEL) Issues Earnings Results, Beats Expectations By $0.08 EPS www.americanbankingnews.com - March 5 at 8:38 PM
	World Champion Swimmer and Twelve-Time Medalist Dara Torres Partners with Vericel for the ‘It’s Your Move’ Campaign finance.yahoo.com - March 5 at 5:10 PM
	Vericel Corp (VCEL) Shares Are Skyrocketing On Record 4Q Revenues finance.yahoo.com - March 5 at 5:10 PM
	Why Vericel Jumped Higher Today finance.yahoo.com - March 5 at 5:10 PM
	XL Group, Treehouse Foods rise; Blue Apron, Dermira fall marketbeat.com - March 5 at 4:54 PM
	Vericel (VCEL) Stock Rating Reaffirmed by BTIG Research www.americanbankingnews.com - March 5 at 4:00 PM
	Vericel (VCEL) Price Target Increased to $14.00 by Analysts at Piper Jaffray Companies www.americanbankingnews.com - March 5 at 1:36 PM
	6 Stocks To Watch For March 5, 2018 - Benzinga www.benzinga.com - March 5 at 9:24 AM
	Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance - GlobeNewswire (press release) globenewswire.com - March 5 at 9:24 AM
	Pre-Market Earnings Report for March 5, 2018 : VCEL, ARQL - Nasdaq www.nasdaq.com - March 3 at 5:23 PM

Vericel (NASDAQ:VCEL) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Vericel (NASDAQ:VCEL) Income Statement, Balance Sheet and Cash Flow Statement

Vericel (NASDAQ VCEL) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff